# A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment

> **NCT05376839** · PHASE1 · TERMINATED · sponsor: **AbbVie** · enrollment: 6 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Cedirogant

## Key facts

- **NCT ID:** NCT05376839
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-07-06
- **Primary completion:** 2022-11-08
- **Final completion:** 2022-11-08
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Strategic considerations
- **Last updated:** 2022-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05376839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05376839, "A Study to Assess Safety of Cedirogant and How Cedirogant Moves Through the Body in Adult Participants With Mild, Moderate and Severe Hepatic Impairment". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT05376839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*